|
| Status |
Public on Oct 24, 2020 |
| Title |
IRAK1/4 and BET bromodomain inhibitions converge on NF-κB blockade and display synergistic antitumor activity in ABC-DLBCL with MYD88L265P mutation |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Diffuse large B cell lymphoma cell lines of the activated B cell subtype (ABC-DLBCL) were treated for 6h with IRAK1/4 inhibitor (50µM) followed or not by a 18h exposure to 500 nM CPI203
We used microarrays to uncover the mechanisms underlying IRAKi+BETi activity in ABC-DLBCL
|
| |
|
| Overall design |
Global RNA expression was done in three ABC-DLBCL cell lines treated in vitro with IRAKi (6h) +/- BETi (18h)
|
| |
|
| Contributor(s) |
Dlouhy Y, Roué G |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Oct 23, 2020 |
| Last update date |
Oct 26, 2020 |
| Contact name |
Gael Roue |
| E-mail(s) |
[email protected]
|
| Organization name |
Josep Carreras Leukaemia Research Institute
|
| Department |
Lymphoma Translational lab
|
| Street address |
Ctra de Can Ruti, Camí de les Escoles s/n
|
| City |
Badalona |
| ZIP/Postal code |
08916 |
| Country |
Spain |
| |
|
| Platforms (1) |
| GPL13667 |
[HG-U219] Affymetrix Human Genome U219 Array |
|
| Samples (12)
|
|
| Relations |
| BioProject |
PRJNA670877 |
Less...
More...